Printer Friendly

New guideline targets COPD exacerbations.

FROM CHEST

The American College of Chest Physicians and the Canadian Thoracic Society have issued new recommendations for reducing the risk of acute exacerbations of COPD.

The guideline, representing the first partnership of its kind between two of the largest thoracic societies in the world, has 33 recommendations based on "an up-to-date, rigorous, evidence-based analysis of current randomized controlled trial data," noted Dr. Gerard J. Criner, professor of pulmonary and critical care medicine, Temple University, Philadelphia, and his associates on the guideline's expert panel.

"Exacerbations are to COPD what myocardial infarctions are to coronary artery disease: They are acute, trajectory changing, and often deadly manifestations of a chronic disease. Exacerbations cause frequent hospital admissions, relapses, and readmissions; contribute to death during hospitalization or shortly thereafter; reduce quality of life dramatically; consume financial resources; and hasten a progressive decline in pulmonary function, a cardinal feature of COPD," Dr. Criner and his associates wrote (CHEST 2015;147:894-942).

Current COPD treatment guidelines state that prevention of exacerbations is possible, but they provide little information about available therapies. The ACCP and CTS jointly commissioned their guideline to address "this important void in COPD management."

Among their recommendations are the following:

* Patients with moderate, severe, or very severe COPD who had an exacerbation within the preceding 4 weeks should undergo pulmonary rehabilitation to prevent further exacerbations. The data do not support pulmonary rehabilitation for those whose most recent exacerbation was more than 4 weeks earlier.

* Smoking cessation treatment is suggested as a component of a comprehensive clinical strategy to prevent COPD exacerbations. Quitting smoking is the only evidence-based intervention that improves COPD prognosis, because it mitigates further declines in lung function and reduces symptoms.

* Education plus case management, to include direct contact with a health care specialist at least monthly, are recommended to prevent acute exacerbations; either measure alone is insufficient.

* The 23-valent pneumococcal vaccine is suggested although evidence does not support the vaccine for preventing acute exacerbations. The vaccine benefits the general health of people aged 65 and older and of all adults who have underlying chronic medical conditions such as COPD.

* Annual influenza vaccination is recommended because of its general benefit and the fact that existing guidelines recommend it for COPD patients.

The guideline addresses the use of numerous medications, alone or in combination, including short- and long-acting beta-2 agonists, short- and long-acting muscarinic antagonists, inhaled corticosteroids, inhaled long-acting anticholinergics, long-term macrolides, oral and IV systemic corticosteroids, roflumilast (when chronic bronchitis is present), oral slow-release theophylline, oral N-acetylcysteine, oral carbocysteine, and statins.

A section on novel therapies includes adenosine A2A-receptor agonists, inhibitors of proinflammatory pathways, and activators of anti-inflammatory pathways. Other approaches include drugs with antioxidant effects, drugs that facilitate lung regeneration, and mucoactive agents.

VITALS

Key clinical point: The American College of Chest Physicians and the Canadian Thoracic Society have issued a guideline for prevention of acute exacerbations of COPD.

Major finding: COPD exacerbations are acute, trajectory changing, and often deadly manifestations of a chronic disease.

Data source: A comprehensive literature review on prevention of acute COPD exacerbations and a compilation of 33 recommendations and suggestions for physicians in clinical practice.

Disclosures: The American College of Chest Physicians, the Canadian Thoracic Society, and the American Thoracic Society supported the project. Dr. Criner reported having no relevant financial disclosures; his associates reported ties to numerous industry sources.

imnews@frontlinemedcom.com
COPYRIGHT 2015 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:PULMONARY MEDICINE
Author:Moon, Mary Ann
Publication:Internal Medicine News
Date:May 15, 2015
Words:558
Previous Article:Commentary: finally, an end to the SGR game of chicken.
Next Article:Home sleep tests' auto scores too low on AHI.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters